CS
GTHX

Candriam SCA’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Candriam SCA’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-870,423
Closed -$21.1M – 832
2020
Q2 		$21.1M Buy
870,423
+510,014
+142% +$8.43M 0.22% 114
2020
Q1 		$9.31M Buy
360,409
+22
+0% +$411 0.1% 224
2019
Q4 		$9.53M Buy
360,387
+57,887
+19% +$1.35M 0.1% 226
2019
Q3 		$6.89M Buy
+302,500
New +$9.54M 0.09% 258

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Candriam SCA's GTHX Position: Q3 2020 in Review

Candriam SCA sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2020, closing a stake of 870,423 shares — an estimated $21.1M sold.

Candriam SCA first reported a position in GTHX in Q3 2019 and held it in 4 quarters. The position peaked at $21.1M in Q2 2020. 118 funds tracked by Wall St. Rank hold GTHX as of Q3 2020.

  • Candriam SCA reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Candriam SCA sold 870,423 G1 Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $21.1M.
  • Candriam SCA first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • Candriam SCA's G1 Therapeutics, Inc. Common Stock position peaked at $21.1M in Q2 2020.
  • 118 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.